Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
WALTHAM, Mass., Feb. 09, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in an analyst-led fireside chat at the Leerink Partners Global Healthcare Conference on Thursday, February 16, 2017 at 2:00 p.m. EST.
A live audio webcast of the discussion will be accessible through the Investors section of the company’s website at www.amagpharma.com, and will be archived for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our products support the health of patients in the areas of women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
